Wegovy vs Mounjaro Side Effects: A Head-to-Head Comparison

Why Cross-Trial Comparisons Have Limits

Both Wegovy and Mounjaro were tested in separate randomized controlled trials with different patient populations, endpoints, and titration schedules. That matters. Comparing numbers across trials is useful for rough benchmarking, but it does not replace a proper head-to-head study.

STEP-1 enrolled 1,961 adults without type 2 diabetes (mean BMI 37.9 kg/m²) and ran for 68 weeks [1]. SURMOUNT-1 enrolled 2,539 adults, also without diabetes (mean BMI 38.0 kg/m²), over 72 weeks [3]. The populations look similar on paper. Baseline A1C, age distribution, and sex ratios were broadly comparable. These parallels make cross-trial comparison more defensible than usual, though not equivalent to randomized evidence.

SURPASS-2 did test tirzepatide directly against semaglutide, but only at the 1 mg dose used for type 2 diabetes, not the 2.4 mg obesity dose [2]. Extrapolating those results to the obesity setting requires caution. "Indirect comparisons should always be interpreted with appropriate uncertainty," the American Gastroenterological Association's 2024 clinical practice guideline notes when discussing anti-obesity medication selection.

With that caveat stated clearly, the available data still reveal meaningful patterns worth examining.

Gastrointestinal Side Effects: The Core Difference

GI symptoms dominate the adverse-event profiles of both medications. Nausea, vomiting, diarrhea, and constipation are the complaints patients report most often, and these are the symptoms most likely to drive treatment discontinuation.

In STEP-1, semaglutide 2.4 mg produced nausea in 44.2% of participants, diarrhea in 31.1%, vomiting in 24.8%, and constipation in 24.2% [1]. Most episodes were mild to moderate. They clustered during the dose-escalation phase (weeks 1 through 16) and tapered as patients reached the maintenance dose.

In SURMOUNT-1, tirzepatide's GI profile looked somewhat milder. At the 5 mg dose, nausea affected 24.0% of participants; at 10 mg, 26.0%; at 15 mg, 33.3% [3]. Vomiting rates ranged from 8.3% (5 mg) to 12.2% (15 mg). Diarrhea ranged from 18.7% to 21.2%. Constipation hovered between 11.7% and 17.1%.

The gap in vomiting rates stands out. Semaglutide 2.4 mg caused vomiting roughly twice as often as tirzepatide 15 mg, despite tirzepatide 15 mg producing greater weight loss (22.5% vs 14.9%). One proposed explanation involves the dual GIP/GLP-1 mechanism. GIP receptor activation may partially buffer the nausea and emetic signals generated by GLP-1 receptor stimulation. Preclinical data in rodent models support this hypothesis, though human mechanistic studies remain limited [4].

The practical takeaway: patients who are highly sensitive to nausea may tolerate tirzepatide better, though individual responses vary widely regardless of which drug is chosen.

Nausea Timing and the Dose-Titration Window

Both drugs use a gradual dose-escalation schedule designed to minimize GI side effects. How these schedules differ explains part of the tolerability gap.

Wegovy escalates from 0.25 mg weekly to the full 2.4 mg dose over 16 weeks, in four-week increments [5]. Mounjaro starts at 2.5 mg weekly and increases to the target dose (5, 10, or 15 mg) in 2.5 mg steps every four weeks, reaching 15 mg by week 20 [6].

The slower ramp with Mounjaro at the highest dose may contribute to fewer acute GI complaints. Clinicians who prescribe these medications frequently report that extending the titration period, or holding at an intermediate dose for an extra four weeks, can reduce nausea with either drug.

"We often advise patients that the first four to six weeks on any GLP-1 receptor agonist will be the roughest period for nausea, and that most people see significant improvement by month three," says the Endocrine Society's 2024 clinical practice guideline on obesity pharmacotherapy.

Dietary adjustments also matter. Eating smaller, more frequent meals, avoiding high-fat foods, and stopping eating before feeling full can reduce the severity of GI symptoms during titration with either medication [5][6].

Serious Adverse Events: Pancreatitis and Gallbladder Disease

Acute pancreatitis is the serious GI event that draws the most concern with incretin-based therapies. Both FDA labels carry warnings about this risk [5][6].

In STEP-1, acute pancreatitis occurred in fewer than 0.2% of semaglutide-treated patients [1]. SURMOUNT-1 reported similarly low pancreatitis rates across all tirzepatide dose groups [3]. Neither trial found a statistically significant increase compared to placebo. A 2023 meta-analysis in The Lancet covering 76 GLP-1 RA trials (N = 90,910) found no increased pancreatitis risk with GLP-1 receptor agonists as a class, though individual case reports continue to appear in post-marketing surveillance.

Gallbladder events, specifically cholelithiasis and cholecystitis, occurred at slightly higher rates than placebo in both programs. STEP-1 reported cholelithiasis in 2.6% of semaglutide patients vs 1.2% on placebo [1]. SURMOUNT-1 reported gallbladder-related events in 0.4% to 1.7% of tirzepatide-treated participants, with higher rates at the 15 mg dose [3]. Rapid weight loss itself increases gallstone risk regardless of the method used, so disentangling the drug effect from the weight-loss effect remains difficult.

Patients with a history of gallbladder disease should discuss this risk with their prescribing physician before starting either medication.

Thyroid C-Cell Tumor Warning

Both Wegovy and Mounjaro carry a boxed warning about thyroid C-cell tumors. This warning originates from rodent carcinogenicity studies in which semaglutide and tirzepatide caused dose-dependent increases in thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in rats [5][6].

The clinical relevance to humans remains uncertain. Rats have far higher densities of GLP-1 receptors on thyroid C-cells than humans do. No causal link between GLP-1 receptor agonists and MTC has been established in human epidemiological studies to date. A 2022 pharmacovigilance analysis published in Diabetes Care examined FDA Adverse Event Reporting System data for all GLP-1 RAs and found no signal for increased MTC incidence over a decade of post-marketing surveillance.

Both drugs are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). No routine thyroid monitoring is recommended for patients without these risk factors.

Discontinuation Rates and Real-World Tolerability

Treatment discontinuation due to adverse events is one of the most practical measures of tolerability. It reflects the side effects severe enough to make patients stop therapy entirely.

In STEP-1, 7.0% of semaglutide-treated participants discontinued for any adverse event, with GI-related discontinuation at approximately 4.5% [1]. In SURMOUNT-1, total adverse-event discontinuation ranged from 4.3% (5 mg) to 7.1% (15 mg), with GI reasons accounting for the majority [3]. The rates are broadly comparable. At the highest tirzepatide dose, discontinuation rates matched those seen with semaglutide 2.4 mg despite greater weight loss.

Real-world data paint a slightly different picture. A 2024 retrospective cohort study using electronic health records found 12-month persistence rates of approximately 40% for semaglutide and 48% for tirzepatide in a commercial insurance population. Cost, insurance coverage, and supply shortages influenced persistence as much as side effects did, making it hard to isolate tolerability from access barriers.

The clinical bottom line: if a patient tolerates the GI side effects through the first 8 to 12 weeks of dose escalation, long-term tolerability with either drug is generally good.

Cardiovascular Safety: Where Wegovy Has Stronger Evidence

Cardiovascular outcomes data currently favor Wegovy, though not because Mounjaro has raised safety concerns.

The SELECT trial (N = 17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% compared to placebo over a median 39.8 months in adults with established cardiovascular disease and overweight or obesity, but without diabetes [7]. This was a landmark result. It established semaglutide as the first anti-obesity medication with proven cardiovascular benefit.

Tirzepatide does not yet have a completed cardiovascular outcomes trial in an obesity-only population. The SURPASS-CVOT trial is ongoing and expected to report results in the coming years. Interim safety data from the SURPASS and SURMOUNT programs have not identified any cardiovascular safety signals [2][3].

For patients whose primary concern is cardiovascular risk reduction alongside weight loss, Wegovy currently has the stronger evidence base. For patients focused purely on tolerability and magnitude of weight loss, the data favor tirzepatide.

Non-GI Side Effects Worth Knowing

Beyond the GI tract, both drugs share a similar non-GI side-effect profile. Headache, fatigue, and injection-site reactions appear in both labels at low single-digit percentages [5][6].

Injection-site reactions (redness, itching, or induration at the injection site) occurred in 3.2% of Wegovy patients in STEP-1 and in roughly 2% to 4% of Mounjaro patients across SURMOUNT-1 dose groups [1][3]. These are generally mild and self-limited.

Hair loss (alopecia) has been reported anecdotally and in post-marketing data for both drugs. In STEP-1, alopecia appeared in 3.0% of semaglutide-treated patients vs 1.0% on placebo [1]. SURMOUNT-1 reported similar low rates. Hair thinning associated with rapid weight loss (telogen effluvium) is a recognized phenomenon independent of drug mechanism and typically reverses once weight stabilizes.

Hypoglycemia is rare with either drug when used without concomitant insulin or sulfonylureas. Both labels recommend dose adjustment of insulin and sulfonylureas when co-prescribed [5][6].

Patients should report persistent abdominal pain, signs of dehydration from vomiting or diarrhea, or any neck mass or dysphagia to their physician promptly.